Arbele, a Hong Kong-based clinical stage biopharmaceutical company, announced on Wednesday that it has dosed its first patient in Australia in Phase I Study of ARB202 intended to treat advanced gastrointestinal cancers patients.

The company is claimed to be the first globally to explore the potential of CDH17xCD3 bispecific T-Cell engager antibody in cancer immunotherapy.

The Phase I trial, a continuous multi-centre, open-label, dose-escalation trial for both the ascending dose (Phase Ia) and dose ranging (Phase Ib/2a) phases, aims to determine the tolerability and/or to be used dose of ARB202. The preliminary impacts on biomarkers and clinical efficacy of the product in GI cancer patients will be examined. Given tolerability potential expansion cohorts will further evaluate the safety and efficacy of ARB202 in specific indication(s) and in combination with other therapy.

Arbele expects to report initial safety, tolerability, and PK/PD data in Q2 2023.